database / gh-secretagogue
MGF
also known as mechano growth factor, IGF-1Ec
Research reference only. The observations below are recorded in the cited literature. Nothing here is advice or a recommendation, and no dosing information is published on this site.
Sequence
Primary structure not characterised in the public records this index draws on. Nothing is shown rather than something invented.
Molecular data
| molecular formula | not characterised |
|---|---|
| molecular weight | not characterised |
| computed backbone mass | not characterised |
| length | not characterised |
| net charge (pH 7.4) | not characterised |
| mean hydropathy | not characterised |
| half-life | not characterised |
| delivery route | not characterised |
| PubChem CID | not characterised |
| PDB | not characterised |
| UniProt parent | P05019 |
Mechanism
Splice variant of IGF-1 expressed after mechanical loading; the E-domain peptide is the studied fragment.
Reported targets: not fully established
Experimental structure
No experimental structure of this peptide is deposited in the PDB. Nothing is rendered here — a predicted fold would not be a structure, and this site does not draw one.
Parent protein
MGF is an alternatively spliced IGF-1 isoform. UniProt P05019 · 195 aa
Reported effects
Each row is an outcome described in the literature indexed for this peptide. Reported in the cited work — not a claim, not a recommendation.
| reported outcome | where it appears |
|---|---|
| satellite cell activation in models | The emerging landscape of performance-enhancing peptides modulating GH-IGF1 … Frontiers in endocrinology 2026 |
| muscle repair signalling | Pretreatment with mechano growth factor E peptide attenuates osteoarthritis … International immunopharmacology 2021 |
Literature (7)
The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration — Frontiers in endocrinology 2026
Performance-enhancing drugs (PEDs) marketed as "research compounds" include unregulated peptides intended to modulate the growth hormone-insulin-like growth factor-1 (GH-IGF-1) axis. The agents most commonly encountered in clinical practice and online self-administration protocols include growth hormone-releasing hormone (GHRH) analogues (e.g., sermorelin, tesamorelin, CJC-1295 with Drug Affinity Complex [DAC], CJC-1295 without DAC), growth hormone secretagogues (GHS; e.g., growth hormone-releasing peptide-2 (GHRP-2), growth hormone-releasing peptide-6 (GHRP-6), hexarelin, ipamorelin), the growth hormone (GH) fragment - AOD9604 (hGH 176-191), and insulin-like growth factor-1 (IGF-1) analogues (e.g., pegylated mechano growth factor (PEG-MGF), IGF-1 Long R3 (IGF-1 LR3)). Reported adverse effects span endocrine and metabolic disturbances (including prolactin and cortisol elevations, appetit…
open access ↗ · PMID 42395176 · DOI 10.3389/fendo.2026.1822475
Pretreatment with mechano growth factor E peptide attenuates osteoarthritis through improving cell proliferation and extracellular matrix synthesis in chondrocytes under severe hypoxia — International immunopharmacology 2021
abstract not reproduced — this record is not open-access, so it is linked rather than copied.
publisher record ↗ · PMID 34015701 · DOI 10.1016/j.intimp.2021.107628
Mechano-growth factor E-domain modulates cardiac contractile function through 14-3-3 protein interactomes — Frontiers in physiology 2022
In the heart, alternative splicing of the igf-I gene produces two isoforms: IGF-IEa and IGF-IEc, (Mechano-growth factor, MGF). The sequence divergence between their E-domain regions suggests differential isoform function. To define the biological actions of MGF's E-domain, we performed in silico analysis of the unique C-terminal sequence and identified a phosphorylation consensus site residing within a putative 14-3-3 binding motif. To test the functional significance of Ser 18 phosphorylation, phospho-mimetic (S/E18) and phospho-null (S/A18) peptides were delivered to mice at different doses for 2 weeks. Cardiovascular function was measured using echocardiography and a pressure-volume catheter. At the lowest ([dose redacted]/day) and highest ([dose redacted]/day) doses, the peptides produced a depression in systolic and diastolic parameters. However, at [dose redacted]/day the peptides produced opposing e…
open access ↗ · PMID 36467694 · DOI 10.3389/fphys.2022.1028345
Surface modification of electrospun fibers with mechano-growth factor for mitigating the foreign-body reaction — Bioactive materials 2021
The implantation of synthetic polymeric scaffolds induced foreign-body reaction (FBR) seriously influence the wound healing and impair functionality recovery. A novel short peptide, mechano-growth factor (MGF), was introduced in this study to modify an electrospun polycaprolactone (PCL) fibrous scaffold to direct the macrophage phenotype transition and mitigate the FBR. In vitro studies discovered the cell signal transduction mechanism of MGF regulates the macrophage polarization via the expression of related genes and proteins. We found that macrophages response the MGF stimuli via endocytosis, then MGF promotes the histone acetylation and upregulates the STAT6 expression to direct an anti-inflammatory phenotype transition. Subsequently, an immunoregulatory electrospun PCL fibrous scaffold was modified by silk fibroin (SF) single-component layer-by-layer assembly, and the SF was decorat…
open access ↗ · PMID 33732968 · DOI 10.1016/j.bioactmat.2021.02.020
Mechano-growth Factor Expression in Colorectal Cancer Investigated With Fluorescent Gold Nanoparticles — Anticancer research 2019
abstract not reproduced — this record is not open-access, so it is linked rather than copied.
publisher record ↗ · PMID 30952709 · DOI 10.21873/anticanres.13276
Detection of insulin analogues and large peptides >2 kDa in urine — Drug testing and analysis 2022
abstract not reproduced — this record is not open-access, so it is linked rather than copied.
publisher record ↗ · PMID 35261185 · DOI 10.1002/dta.3249
Detection and in vitro metabolism of the confiscated peptides BPC 157 and MGF R23H — Drug testing and analysis 2017
abstract not reproduced — this record is not open-access, so it is linked rather than copied.
publisher record ↗ · PMID 28035768 · DOI 10.1002/dta.2152
Related
BPC-157
healing · 8 citations
Ipamorelin
gh-secretagogue · 8 citations
CJC-1295
gh-secretagogue · 8 citations
Sermorelin
gh-secretagogue · 8 citations
Tesamorelin
gh-secretagogue · 8 citations
GHRP-2
gh-secretagogue · 8 citations